Durect

(DRRX) - Get Report

jumped 5.7% to $3.70 after investment research firm Susquehanna Financial Group initiated coverage of the stock with a positive rating.

Citigroup downgraded

AstraZeneca

(AZN) - Get Report

to a hold rating from a buy, sending shares 1.3% lower to $61.35. Citigroup also downgraded generic drugmaker

Endo Pharmaceuticals

(ENDP) - Get Report

from a buy rating to a hold, with a price target of $34. Shares fell 1.4% to $31.24.

Abraxis BioScience

(ABBI)

named a chief operating officer and a leadership team for its pharmaceutical products division. Frank Harmon, former head of global operations will become COO and Thomas H. Silberg will assume the role of president of the pharmaceuticals business. Shares rose 0.5% to $25.10.

Other movers included

Acambis

(ACAM) - Get Report

, whose shares lost 8.5% to $5.08,

Seattle Genetics

(SGEN) - Get Report

, up 0.5% to $4.44 and

Keryx

(KERX) - Get Report

, down 1.6% to $13.06.

King Pharmaceuticals

(KG)

rose 1.6% to $16.52,

Replidyne

(RDYN)

was up 6.5% to $10.05,

Neose Technologies

(NTEC) - Get Report

added 2.5% to $2.43,

Human Genome Sciences

(HGSI)

gained 2.9% to $11.40, and

Forest Laboratories

(FRX)

was up 4.3% to $47.97.